Amgen (AMGN) to Pay $25 Million to Settle Kickback Allegations  
4/17/2013 8:19:21 AM

Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the Department of Justice announced on Tuesday. The DOJ charged that the world's largest biotechnology company violated the False Claims Act through kickbacks paid to Omnicare Inc, Kindred Healthcare Inc and PharMerica Corp in exchange for switching Medicare and Medicaid patients to Aranesp to treat their anemia. "We will continue to pursue pharmaceutical companies that pay kickbacks to long-term care pharmacy providers to influence drug-prescribing decisions," Stuart Delery, acting assistant attorney general for the Justice Department's Civil Division, said in a statement. "Patients in skilled nursing facilities deserve care that is free of improper financial influences," he added.